Jonsson Patrik
Known title: SVP&Pres, LLY Imm, LLY USA&CCOCIK: 0001786054
Associated companies
Transaction History
| LLY | ▼ Sell | Open Market | 6,500 | $7.6M | 8/17/2026 | View on chart |
| LLY | ▲ Buy | Grant | 4,818 | $5.0M | 2/9/2026 | View on chart |
| LLY | ▲ Buy | Option Exercise | 3,930 | $0 | 2/1/2026 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,752 | $1.8M | 2/1/2026 | View on chart |
| LLY | ▲ Buy | Grant | 7,170 | $6.2M | 2/10/2025 | View on chart |
| LLY | ▲ Buy | Option Exercise | 3,433 | $0 | 2/1/2025 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,536 | $1.2M | 2/1/2025 | View on chart |
| LLY | ▲ Buy | Grant | 5,362 | $4.0M | 2/12/2024 | View on chart |
| LLY | ▲ Buy | Option Exercise | 4,124 | $0 | 2/1/2024 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,844 | $1.2M | 2/1/2024 | View on chart |
| LLY | ▼ Sell | Open Market | 6,000 | $2.6M | 6/1/2023 | View on chart |
| LLY | ▲ Buy | Grant | 7,886 | $2.7M | 2/10/2023 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 2,997 | $1.0M | 2/1/2023 | View on chart |
| LLY | ▲ Buy | Option Exercise | 6,690 | $0 | 2/1/2023 | View on chart |
| LLY | ▼ Sell | Open Market | 673 | $187K | 3/17/2022 | View on chart |
| LLY | ▼ Sell | Open Market | 675 | $167K | 3/1/2022 | View on chart |
| LLY | ▲ Buy | Grant | 2,036 | $495K | 2/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill
The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.